Navigation Links
nContact, Inc. Launches New Corporate Websites
Date:10/26/2011

MORRISVILLE, N.C., Oct. 26, 2011 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, announced today the launch of its new corporate websites, www.ncontactinc.eu and www.ncontactinc.com. The design of the new corporate sites reflects the evolution of nContact's technology and the market for treating cardiac arrhythmias that affect millions of people worldwide.

"The new websites are excellent educational references that highlight how our technology is being utilized in the clinical setting to reach new and previously underserved markets," said John P. Funkhouser, President and CEO of nContact.  "This is an important step for our company that reflects our ever evolving technology and approach to expanding available treatments for a patient population who has historically had limited options."

The enhanced websites provide an in-depth view of nContact's Numeris™ and EPi-Sense™ Guided Coagulation Systems with VisiTrax®, expanded physician resources and detailed images and animation videos to build awareness among physicians and patients looking to explore options for the treatment of cardiac arrhythmias.

About nContact, Inc.nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris™ and EPi-Sense™ Coagulation Systems with VisiTrax® have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.Media ContactsBeth Rose

Kimberly MuscaranContact, Inc

The Ruth Group T (919)655-1566

T (646) 536-7011  brose@ncontactinc.com

kmuscara@theruthgroup.com
'/>"/>

SOURCE nContact, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service ... as Regional Account Manager for the Northeast and Florida regions. In this role, ... their obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge ...
(Date:7/25/2017)... D.C. (PRWEB) , ... July 25, 2017 , ... ... and their clients, today announced it will be exhibiting and providing demos of ... at the Walter E. Washington Convention Center in Washington D.C. from August 3-6, ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina ... Negrette has more than a decade of experience in psychiatry, treating clients in ... fighting addictions, eating disorders, psychotic and manic conditions, as well as those who ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric ... , The Emergency Room opened early March, making it the first SignatureCare ... things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re ...
(Date:7/24/2017)... City, MO (PRWEB) , ... July 24, 2017 , ... ... the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
Breaking Medicine News(10 mins):